Extrusion International 4-2025-USA

31 Extrusion International 4/2025 in Orlando, Florida, from Septem - ber 22-25, 2025, the conference is a chance to explore leadership, ad - vocacy, and market trends, all while focusing on a sustainable future for all. For more information about the National Plastics Conference and to register for the event, visit https://nationalplasticsconference.org Acquisition ESTEVE acquires Regis Technolo- gies, a United States-based Contract Development and Manufacturing Organization (CDMO), headquar - tered in Chicago.  This strategic move allows ESTEVE CDMO (ac- tively operating under the Esteve Química brand) a physical presence in the United States, expanding its contract development and manu- facturing solutions for innovative small-molecule active pharmaceu- tical ingredients (APIs) across the entire drug development lifecycle from pre-clinical to commercial manufacturing.  For over 65 years, Regis Tech - nologies has been a US-based API CDMO, offering a broad spectrum of services, including process re - search & development, analytical & stability, cGMP API manufacturing, CMC support, and a variety of chro - matography products. “We are proud to strengthen our CDMO solutions for pharmaceutical innovators through this acquisition, while welcoming around 70 skilled professionals to our US team”, said Joan Petit, Chief Industrial Opera - tions Officer of ESTEVE and General Manager of Esteve CDMO (Esteve Química). Andrea Oro, Global Head of Com - mercial Operations and Strategy, added, “This acquisition enhances our early-stage development capa- bilities and expands our global man- ufacturing footprint, allowing us to have an integrated service offering to better respond to our customers’ needs.” “We are happy to join a company that shares our same values, a com - pany that is also family-owned, with more than 90 years of experience, that is committed to people and fo- cused on delivering long-term value to customers”, added Scott Ala - deen, President and CEO of Regis Technologies. ESTEVE CDMO (Esteve Química) is a global pure-play third-party CDMO, specializing in high-quality small-molecule active pharmaceuti- cal ingredients and pharmaceutical intermediates, providing technolo - gies such as Spray Drying and high- potency APIs (HPAPIs) manufactur- ing. RBC Capital Markets served as financial advisor for ESTEVE, and Wombat Capital Markets served as financial advisor for Regis Technolo - gies, for this operation. ESTEVE www.esteve.com Regis Technologies, Inc. www.registech.com